Allgens(SH:688613) Zheng Quan Zhi Xing·2025-08-30 23:26Core Insights - Aojing Medical (688613) reported a net profit decline of 13.52% year-on-year for the first half of 2025, with total revenue of 100 million yuan, a slight decrease of 0.2% compared to the previous year [1] - The second quarter showed a revenue increase of 8.88% year-on-year, with a significant net profit increase of 203.59% [1] Financial Performance - Total revenue for 2025 was 100 million yuan, unchanged from 2024, with a net profit of 797.53 million yuan, down 13.52% [1] - Gross margin decreased to 63.12%, down 17.75% year-on-year, while net margin improved to 5.53%, up 12.23% [1] - Total expenses (selling, administrative, and financial) amounted to 52.27% of revenue, a decrease of 13.41% year-on-year [1] Key Metrics - Earnings per share (EPS) decreased to 0.06 yuan, down 14.29% year-on-year, while operating cash flow per share improved to -0.03 yuan, an increase of 55.48% [1] - The company's return on invested capital (ROIC) has been historically low, with a median of 9.28% since its listing, and a particularly poor ROIC of -1.21% in 2024 [3] - The company maintains a healthy cash position, indicating good solvency [3]